A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
The primary objective of this phase I study is to evaluate the safety and potential efficacy
and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand
conjugated drugs in patients with advanced solid tumors.